EUVIMEDEUVIMED entdecken
Crossref

Circulating tumor DNA as a biomarker to guide treatment escalation and de-escalation in nonsmall cell lung cancer: A review of the current evidence

Nathickshi Chandrasegar, Abigail Kupka, Christina Haaf, Noor Naffakh

NCODA Oncology and Hematology Meeting Abstracts · 28.10.2026 · 2 (2)

DOI: 10.67209/icoz2665 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 28.10.2026. Verfasst von Nathickshi Chandrasegar und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for 85% of lung cancers. While treatment for NSCLC has advanced across all stages, there remains a need for reliable tools to identify which patients need additional therapy versus who can safely de-escalate. Standard imaging often misses minimal residual disease (MRD), and fixed treatment durations fail to account for individual response. Circulating tumor DNA (ctDNA) offers a minimally invasive approach for real-time assessment of molecular response and residual disease, potentially overcoming limitations of radiographic monitoring and tissue-based testing. This review examines ctDNA’s potential to guide treatment escalation and de-escalation in patients with NSCLC.

Objectives

Summarize current evidence and limitations regarding the use of ctDNA to inform treatment escalation, de-escalation, and surveillance strategies in nonsmall cell lung cancer (NSCLC).

Methods

A targeted literature search was conducted using PubMed and EMBASE to identify studies evaluating ctDNA in NSCLC. Search terms included “circulating tumor DNA”, “non-small cell lung cancer”, “treatment escalation,” and “de-escalation.” Results: In early-stage, resectable disease, TRACERx (ctDNA across diagnosis, neoadjuvant therapy, and surgery in resectable NSCLC) and the LUCID study (postoperative ctDNA monitoring in surgically/chemoradiation-treated stage I–III NSCLC patients) demonstrated that postoperative ctDNA clearance is associated with excellent clinical outcomes. In contrast, persistent ctDNA indicating MRD, particularly when assessed longitudinally rather than at a single timepoint, identifies patients who may be undertreated with standard adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy. In metastatic disease, Dong et al. demonstrated the feasibility of ctDNA-guided TKI discontinuation in selected patients, supporting further investigation of ctDNA-directed treatment de-escalation strategies (median progression-free survival [PFS] 18.4 months off-therapy, 96% re-clearing ctDNA). In contrast, BR.36, evaluating pembrolizumab in advanced NSCLC, and exploratory analyses from FLAURA and AURA3 evaluating osimertinib in EGFR-mutated NSCLC suggest that persistent ctDNA during treatment is associated with poor outcomes and may help identify patients requiring closer monitoring or alternative therapeutic strategies.

Discussion

Across studies in resectable and advanced/metastatic NSCLC, ctDNA clearance identifies patients who may be candidates for treatment de-escalation, while persistent ctDNA may identify those who may benefit from treatment escalation or closer monitoring. ctDNA and radiographic assessment provide complementary, rather than redundant, information. In metastatic NSCLC treated with chemoimmunotherapy, combining ctDNA with imaging predicted PFS and overall survival (OS) better than either alone. In resectable disease, longitudinal ctDNA monitoring can detect residual or recurrent disease before it is visible on imaging. These findings support ctDNA as a valuable tool; however, ongoing randomized trials, such as CTONG 2105 and 2201, may better inform whether ctDNA can safely guide treatment selection and personalization in routine clinical practice.

Conclusions

Current evidence supports ctDNA as a powerful prognostic biomarker, but prospective randomized trials are needed to establish the role of ctDNA-guided escalation and de-escalation in NSCLC. Funding: Not applicable.

Zitieren

APA

Chandrasegar, N., Kupka, A., Haaf, C., & Naffakh, N. (2026). Circulating tumor DNA as a biomarker to guide treatment escalation and de-escalation in nonsmall cell lung cancer: A review of the current evidence. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/icoz2665

Vancouver

Chandrasegar N, Kupka A, Haaf C, Naffakh N. Circulating tumor DNA as a biomarker to guide treatment escalation and de-escalation in nonsmall cell lung cancer: A review of the current evidence. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/icoz2665

BibTeX
@article{Chandrasegar2026,
  author = {Chandrasegar, Nathickshi and Kupka, Abigail and Haaf, Christina and Naffakh, Noor},
  title = {Circulating tumor DNA as a biomarker to guide treatment escalation and de-escalation in nonsmall cell lung cancer: A review of the current evidence},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.67209/icoz2665}
}
Kostenlos starten →